Can Mehmet Mustafa, Kaymaz Cihangir
Kartal Koşuyolu Yüksek Ihtisas Eğitim ve Araştirma Hastanesi, Kardiyoloji Kliniği, Istanbul, Türkiye.
Anadolu Kardiyol Derg. 2010 Aug;10 Suppl 1:36-42. doi: 10.5152/akd.2010.117.
Pulmonary arterial hypertension (PAH) is a rare, fatal and progressive disease. There is an acceleration in the advent of new therapies in parallel to the development of the knowledge about etiogenesis and pathogenesis of PAH. Therefore, to optimize the goals of PAH-specific treatment and to determine the time to shift from monotherapy to combination therapy, simple, objective and reproducible end-points, which may predict the disease severity, progression rate and life expectancy are needed. The adventure of end points in PAH has started with six minute walk distance and functional capacity, and continues with new parameters (biochemical marker, time to clinical worsening, echocardiography and magnetic resonance imaging etc.), which can better reflect the clinical outcome.
肺动脉高压（PAH）是一种罕见、致命且进行性的疾病。随着对PAH病因学和发病机制认识的发展，新疗法的出现也在加速。因此，为了优化PAH特异性治疗的目标并确定从单药治疗转向联合治疗的时机，需要简单、客观且可重复的终点指标，这些指标可以预测疾病的严重程度、进展速度和预期寿命。PAH终点指标的探索始于六分钟步行距离和功能能力，如今仍在继续，新的参数（生化标志物、临床恶化时间、超声心动图和磁共振成像等）能够更好地反映临床结果。
